Trial Profile
Real-World Experience of Idarucizumab for Reversal of Dabigatran
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 20 Sep 2018
Price :
$35
*
At a glance
- Drugs Idarucizumab (Primary)
- Indications Blood coagulation disorders
- Focus Therapeutic Use
- 20 Sep 2018 New trial record
- 11 Sep 2018 Results published in the American Journal of Cardiovascular Drugs